| William Bradley Rogers, MD | |
|
2340 Knob Creek Rd, Suite 720, Johnson City, TN 37604-2977 | |
| (423) 926-6112 | |
| Not Available |
| Full Name | William Bradley Rogers |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 16 Years |
| Location | 2340 Knob Creek Rd, Johnson City, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043463029 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 49623 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Franklin Woods Community Hospital | Johnson city, TN | Hospital |
| Wellmont Bristol Regional Medical Center | Bristol, TN | Hospital |
| Johnson City Medical Center | Johnson city, TN | Hospital |
| Wellmont Holston Valley Medical Center | Kingsport, TN | Hospital |
| Johnston Memorial Hospital | Abingdon, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Holston Medical Group Pc | 8224935754 | 221 |
News Archive
RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840).
A new proof-of-concept study details how an automated system driven by artificial intelligence can design, build, test and learn complex biochemical pathways to efficiently produce lycopene, a red pigment found in tomatoes and commonly used as a food coloring, opening the door to a wide range of biosynthetic applications, researchers report.
An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, has identified the microtubule-associated protein tau (MAPT) gene as increasing the risk for developing Alzheimer's disease (AD).
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers and published online today in the New England Journal of Medicine.
Increased understanding of the Skp2 gene and its relation to cellular senescence may lead to the development of novel agents that can suppress tumor development in common types of cancer, researchers from The University of Texas M. D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center report in the journal Nature.
› Verified 3 days ago
| Entity Name | Holston Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831110667 PECOS PAC ID: 8224935754 Enrollment ID: O20031216000416 |
News Archive
RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840).
A new proof-of-concept study details how an automated system driven by artificial intelligence can design, build, test and learn complex biochemical pathways to efficiently produce lycopene, a red pigment found in tomatoes and commonly used as a food coloring, opening the door to a wide range of biosynthetic applications, researchers report.
An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, has identified the microtubule-associated protein tau (MAPT) gene as increasing the risk for developing Alzheimer's disease (AD).
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers and published online today in the New England Journal of Medicine.
Increased understanding of the Skp2 gene and its relation to cellular senescence may lead to the development of novel agents that can suppress tumor development in common types of cancer, researchers from The University of Texas M. D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center report in the journal Nature.
› Verified 3 days ago
| Entity Name | Johnson City Urological Clinic, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578689253 PECOS PAC ID: 5799720082 Enrollment ID: O20050627001275 |
News Archive
RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840).
A new proof-of-concept study details how an automated system driven by artificial intelligence can design, build, test and learn complex biochemical pathways to efficiently produce lycopene, a red pigment found in tomatoes and commonly used as a food coloring, opening the door to a wide range of biosynthetic applications, researchers report.
An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, has identified the microtubule-associated protein tau (MAPT) gene as increasing the risk for developing Alzheimer's disease (AD).
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers and published online today in the New England Journal of Medicine.
Increased understanding of the Skp2 gene and its relation to cellular senescence may lead to the development of novel agents that can suppress tumor development in common types of cancer, researchers from The University of Texas M. D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center report in the journal Nature.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| William Bradley Rogers, MD 2340 Knob Creek Rd, Suite 720, Johnson City, TN 37604-2977 Ph: (423) 926-6112 | William Bradley Rogers, MD 2340 Knob Creek Rd, Suite 720, Johnson City, TN 37604-2977 Ph: (423) 926-6112 |
News Archive
RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840).
A new proof-of-concept study details how an automated system driven by artificial intelligence can design, build, test and learn complex biochemical pathways to efficiently produce lycopene, a red pigment found in tomatoes and commonly used as a food coloring, opening the door to a wide range of biosynthetic applications, researchers report.
An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, has identified the microtubule-associated protein tau (MAPT) gene as increasing the risk for developing Alzheimer's disease (AD).
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers and published online today in the New England Journal of Medicine.
Increased understanding of the Skp2 gene and its relation to cellular senescence may lead to the development of novel agents that can suppress tumor development in common types of cancer, researchers from The University of Texas M. D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center report in the journal Nature.
› Verified 3 days ago
Dr. William Jefferson Terry Jr., M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 400 N State Of Franklin Rd, Johnson City, TN 37604 Phone: 423-431-6111 | |
Dr. John Mark Kolski, MD Urology Medicare: Not Enrolled in Medicare Practice Location: James H. Quillen/vamc, Corner Of Sidney And Lamont, Johnson City, TN 37684 Phone: 423-926-1171 | |
Dr. Bill N Boswell, M.D. Urology Medicare: Medicare Enrolled Practice Location: 508 Princeton Rd, Suite 104, Johnson City, TN 37601 Phone: 423-928-0168 Fax: 423-928-5141 | |
Thomas B Mcginnis, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 300 W Watauga Ave, Johnson City, TN 37604 Phone: 423-926-6112 Fax: 423-434-0278 | |
Wayne P Tongco, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2340 Knob Creek Rd, Suite 720, Johnson City, TN 37604 Phone: 423-926-6112 Fax: 423-434-0278 | |
Dr. Lincoln Todd Olsen, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2340 Knob Creek Rd, Suite 720, Johnson City, TN 37604 Phone: 423-926-6112 Fax: 423-434-0278 |